{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:39:26Z","timestamp":1791052766862,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008856","name":"Zhejiang Provincial Health Commission","doi-asserted-by":"publisher","award":["2022ZZ009"],"award-info":[{"award-number":["2022ZZ009"]}],"id":[{"id":"10.13039\/501100008856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004863","name":"Zhejiang Chinese Medical University","doi-asserted-by":"publisher","award":["2022GJYY021"],"award-info":[{"award-number":["2022GJYY021"]}],"id":[{"id":"10.13039\/501100004863","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008327","name":"Zhejiang University of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijbiomac.2025.143541","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T02:25:32Z","timestamp":1745634332000},"page":"143541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P4","title":["Targeting type II NADH dehydrogenase in tuberculosis treatment: A review"],"prefix":"10.1016","volume":"310","author":[{"given":"Han","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Jie","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni-Pi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Dong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.143541_bb0005","doi-asserted-by":"crossref","first-page":"1027394","DOI":"10.3389\/fcimb.2022.1027394","article-title":"The evolving biology of Mycobacterium tuberculosis drug resistance","volume":"12","author":"Jones","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0010","author":"2023 W. H. Organization"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.143541_bb0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cmi.2016.10.008","article-title":"Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis","volume":"23","author":"Dheda","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.143541_bb0020","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1021\/acs.accounts.0c00878","article-title":"Strategies to combat multi-drug resistance in tuberculosis","volume":"54","author":"Singh","year":"2021","journal-title":"Acc. Chem. Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.143541_bb0025","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/jam.14478","article-title":"Recent updates on drug resistance in Mycobacterium tuberculosis","volume":"128","author":"Singh","year":"2020","journal-title":"J. Appl. Microbiol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143541_bb0030","doi-asserted-by":"crossref","first-page":"19431","DOI":"10.1038\/s41598-021-98862-4","article-title":"Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid","volume":"11","author":"G\u00f3mez-Gonz\u00e1lez","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101900","article-title":"Prevalence of long-term physical sequelae among patients treated with multi-drug and extensively drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"57","author":"Akalu","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.143541_bb0040","first-page":"753","article-title":"Kekkaku","volume":"81","author":"Tomioka","year":"2006","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0045","doi-asserted-by":"crossref","unstructured":"BR Bloom, R Atun, T Cohen, C Dye, H Fraser, GB Gomez, G Knight, M Murray, E Nardell, E Rubin, J Salomon, A Vassall, G Volchenkov, R. White, D. Wilson, P. Yadav, (2017). Tuberculosis. In K. K. Holmes (Eds.) et. al., Major Infectious Diseases. (3rd ed.). (The International Bank for Reconstruction and Development \/ The World Bank).","DOI":"10.1596\/978-1-4648-0524-0_ch11"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.143541_bb0050","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3724\/zdxbyxb-2022-0454","article-title":"The past, present and future of tuberculosis treatment. Zhejiang da xue xue bao","volume":"51","author":"Bi","year":"2022","journal-title":"Yi xue ban = Journal of Zhejiang University. Medical sciences"},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.micres.2020.126674","article-title":"Human tuberculosis and Mycobacterium tuberculosis complex: a review on genetic diversity, pathogenesis and omics approaches in host biomarkers discovery","volume":"246","author":"Kanabalan","year":"2021","journal-title":"Microbiol. Res."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0060","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijbiomac.2022.05.124","article-title":"A review on enzyme complexes of electron transport chain from Mycobacterium tuberculosis as promising drug targets","volume":"212","author":"Anand","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"33","key":"10.1016\/j.ijbiomac.2025.143541_bb0065","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1073\/pnas.0711697105","article-title":"The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis","volume":"105","author":"Rao","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.143541_bb0070","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/14728222.2017.1327577","article-title":"Type-II NADH dehydrogenase (NDH-2): a promising therapeutic target for antitubercular and antibacterial drug discovery","volume":"21","author":"Sellamuthu","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.143541_bb0075","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/17460441.2020.1696771","article-title":"Emerging opportunities of exploiting mycobacterial electron transport chain pathway for drug-resistant tuberculosis drug discovery","volume":"15","author":"Roy","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.143541_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40121-013-0009-3","article-title":"A review of the evidence for using Bedaquiline (TMC207) to treat multi-drug resistant tuberculosis","volume":"2","author":"Fox","year":"2013","journal-title":"Infect. Dis. Ther."},{"issue":"5707","key":"10.1016\/j.ijbiomac.2025.143541_bb0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.143541_bb0090","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02530-18","article-title":"High prevalence of Bedaquiline resistance in treatment-naive tuberculosis patients and verapamil effectiveness","volume":"63","author":"Ghajavand","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.143541_bb0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1039\/D3MD00587A","article-title":"Cytochrome bd oxidase: an emerging anti-tubercular drug target","volume":"15","author":"Saha","year":"2024","journal-title":"RSC Med Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143541_bb0100","first-page":"24","article-title":"Bioenergetics of Mycobacterium: an emerging landscape for drug discovery","volume":"7","author":"Iqbal","year":"2018","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0105","doi-asserted-by":"crossref","unstructured":"D Bald, C Villellas, P Lu, A Koul, (2017). Targeting energy metabolism in Mycobacterium tuberculosis, a new paradigm in Antimycobacterial drug discovery. mBio, 8(2), e00272\u201317. doi:https:\/\/doi.org\/10.1128\/mBio.00272-17.","DOI":"10.1128\/mBio.00272-17"},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113139","article-title":"Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis","volume":"212","author":"Urban","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143541_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.353","article-title":"Mycobacterium tuberculosis: pathogenesis and therapeutic targets","volume":"4","author":"Yang","year":"2023","journal-title":"MedComm"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.143541_bb0120","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.bmc.2019.02.026","article-title":"3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel","volume":"27","author":"Sutherland","year":"2019","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143541_bb0125","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02477-21","article-title":"Sudapyridine (WX-081), a novel compound against Mycobacterium tuberculosis","volume":"10","author":"Yao","year":"2022","journal-title":"Microbiology spectrum"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143541_bb0130","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02155-18","article-title":"In vitro and in vivo activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis","volume":"63","author":"Xu","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"18","key":"10.1016\/j.ijbiomac.2025.143541_bb0135","doi-asserted-by":"crossref","first-page":"10331","DOI":"10.3390\/ijms231810331","article-title":"Response of Mycobacterium smegmatis to the cytochrome bcc inhibitor Q203","volume":"23","author":"Chauhan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.143541_bb0140","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01045-23","article-title":"Synthetic lethality of Mycobacterium tuberculosis NADH dehydrogenases is due to impaired NADH oxidation","volume":"14","author":"Xu","year":"2023","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143541_bb0145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.gene.2014.08.024","article-title":"Roles of the two type II NADH dehydrogenases in the survival of Mycobacterium tuberculosis in vitro","volume":"550","author":"Awasthy","year":"2014","journal-title":"Gene"},{"issue":"13","key":"10.1016\/j.ijbiomac.2025.143541_bb0150","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1002\/anie.201800260","article-title":"Small molecules targeting Mycobacterium tuberculosis type II NADH dehydrogenase exhibit Antimycobacterial activity","volume":"57","author":"Harbut","year":"2018","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tube.2016.02.003","article-title":"Neuroleptic drugs in the treatment of tuberculosis: minimal inhibitory concentrations of different phenothiazines against Mycobacterium tuberculosis","volume":"98","author":"Vesenbeckh","year":"2016","journal-title":"Tuberculosis (Edinb.)"},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0160","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/400_2007_028","article-title":"The three families of respiratory NADH dehydrogenases","volume":"45","author":"Kerscher","year":"2008","journal-title":"Results Probl. Cell Differ."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.143541_bb0165","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/MMBR.68.4.603-616.2004","article-title":"New insights into type II NAD(P)H:quinone oxidoreductases","volume":"68","author":"Melo","year":"2004","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"38","key":"10.1016\/j.ijbiomac.2025.143541_bb0170","doi-asserted-by":"crossref","first-page":"15247","DOI":"10.1073\/pnas.1210059109","article-title":"The structure of the yeast NADH dehydrogenase (Ndi1) reveals overlapping binding sites for water- and lipid-soluble substrates","volume":"109","author":"Iwata","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Pt 10","key":"10.1016\/j.ijbiomac.2025.143541_bb0175","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1107\/S2053230X17013073","article-title":"Crystal structure of type II NADH:quinone oxidoreductase from Caldalkalibacillus thermarum with an improved resolution of 2.15\u00a0\u00c5","volume":"73","author":"Nakatani","year":"2017","journal-title":"Acta Crystallogr F Struct Biol Commun."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.143541_bb0180","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/mmi.13120","article-title":"Type-II NADH:quinone oxidoreductase from Staphylococcus aureus has two distinct binding sites and is rate limited by quinone reduction","volume":"98","author":"Sena","year":"2015","journal-title":"Mol. Microbiol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143541_bb0185","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1021\/acs.jmedchem.6b01733","article-title":"Target elucidation by Cocrystal structures of NADH-ubiquinone oxidoreductase of plasmodium falciparum (PfNDH2) with small molecule to eliminate drug-resistant malaria","volume":"60","author":"Yang","year":"2017","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.143541_bb0190","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1111\/1462-2920.13352","article-title":"Type II NADH:quinone oxidoreductase family: phylogenetic distribution, structural diversity and evolutionary divergences","volume":"18","author":"Marreiros","year":"2016","journal-title":"Environ. Microbiol."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0195","doi-asserted-by":"crossref","first-page":"42303","DOI":"10.1038\/srep42303","article-title":"Structural and functional insights into the catalytic mechanism of the type II NADH:quinone oxidoreductase family","volume":"7","author":"Marreiros","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143541_bb0200","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/mmi.12507","article-title":"Structure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generation","volume":"91","author":"Heikal","year":"2014","journal-title":"Mol. Microbiol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.143541_bb0205","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1021\/bi4013897","article-title":"Mycobacterium tuberculosis type II NADH-menaquinone oxidoreductase catalyzes electron transfer through a two-site ping-pong mechanism and has two quinone-binding sites","volume":"53","author":"Yano","year":"2014","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143541_bb0210","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/abbi.2001.2293","article-title":"Kinetic characterization of the rotenone-insensitive internal NADH: ubiquinone oxidoreductase of mitochondria from Saccharomyces cerevisiae","volume":"389","author":"Vel\u00e1zquez","year":"2001","journal-title":"Arch. Biochem. Biophys."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143541_bb0215","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1074\/jbc.M411217200","article-title":"HDQ (1-hydroxy-2-dodecyl-4(1H)quinolone), a high affinity inhibitor for mitochondrial alternative NADH dehydrogenase: evidence for a ping-pong mechanism","volume":"280","author":"Eschemann","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.143541_bb0220","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1074\/jbc.M610646200","article-title":"Roles of bound quinone in the single subunit NADH-quinone oxidoreductase (Ndi1) from Saccharomyces cerevisiae","volume":"282","author":"Yamashita","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0225","doi-asserted-by":"crossref","first-page":"40165","DOI":"10.1038\/srep40165","article-title":"The mechanism of catalysis by type-II NADH:quinone oxidoreductases","volume":"7","author":"Blaza","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.143541_bb0230","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/mmi.13120","article-title":"Type-II NADH:quinone oxidoreductase from Staphylococcus aureus has two distinct binding sites and is rate limited by quinone reduction","volume":"98","author":"Sena","year":"2015","journal-title":"Mol. Microbiol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.143541_bb0235","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1021\/acsinfecdis.4c00710","article-title":"2-aryl-Benzoimidazoles as type II NADH dehydrogenase inhibitors of Mycobacterium tuberculosis","volume":"10","author":"Saha","year":"2024","journal-title":"ACS infectious diseases"},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.143541_bb0240","first-page":"5335","article-title":"Promising Antimycobacterial activities of flavonoids against Mycobacterium sp","volume":"27","author":"Rabaan","year":"2022","journal-title":"Drug Targets: A Comprehensive Review. Molecules (Basel, Switzerland)"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.143541_bb0245","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/biom12101356","article-title":"Glycosylated flavonoid compounds as potent CYP121 inhibitors of Mycobacterium tuberculosis","volume":"12","author":"Bajrai","year":"2022","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.143541_bb0250","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/ja.2013.111","article-title":"A secondary mode of action of polymyxins against gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity","volume":"67","author":"Deris","year":"2014","journal-title":"J. Antibiot."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.143541_bb0255","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1574-6968.2008.01451.x","article-title":"Identification of new inhibitors for alternative NADH dehydrogenase (NDH-II)","volume":"291","author":"Mogi","year":"2009","journal-title":"FEMS Microbiol. Lett."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.143541_bb0260","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbabio.2018.03.014","article-title":"Structure of the NDH-2 - HQNO inhibited complex provides molecular insight into quinone-binding site inhibitors","volume":"1859","author":"Petri","year":"2018","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143541_bb0265","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/jm201179h","article-title":"Identification, design and biological evaluation of bisaryl quinolones targeting plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2)","volume":"55","author":"Pidathala","year":"2012","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.143541_bb0270","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1073\/pnas.0500469102","article-title":"Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs","volume":"102","author":"Weinstein","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.143541_bb0275","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1021\/jacs.9b10254","article-title":"Unprecedented properties of Phenothiazines unraveled by a NDH-2 bioelectrochemical assay platform","volume":"142","author":"Nakatani","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.143541_bb0280","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/187152607781001781","article-title":"Type II NADH: menaquinone oxidoreductase of Mycobacterium tuberculosis","volume":"7","author":"Teh","year":"2007","journal-title":"Infect. Disord. Drug Targets"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.143541_bb0285","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/dks483","article-title":"Antitubercular pharmacodynamics of phenothiazines","volume":"68","author":"Warman","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.143541_bb0290","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1073\/pnas.1721545115","article-title":"Plasticity of Mycobacterium tuberculosis NADH dehydrogenases and their role in virulence","volume":"115","author":"Vilch\u00e8ze","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143541_bb0295","first-page":"1","article-title":"Phenothiazines as a solution for multidrug resistant tuberculosis: from the origin to present","volume":"18","author":"Kristiansen","year":"2015","journal-title":"International microbiology\u202f: the official journal of the Spanish Society for Microbiology"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143541_bb0300","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/47.5.505","article-title":"Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy","volume":"47","author":"Amaral","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143541_bb0305","first-page":"3","article-title":"Thioridazine: a non-antibiotic drug highly effective, in combination with first line anti-tuberculosis drugs, against any form of antibiotic resistance of Mycobacterium tuberculosis due to its multi-mechanisms of action","volume":"6","author":"Amaral","year":"2017","journal-title":"Antibiotics (Basel, Switzerland)"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.143541_bb0310","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/jac\/dku036","article-title":"Novel non-neuroleptic phenothiazines inhibit Mycobacterium tuberculosis replication","volume":"69","author":"Salie","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0315","article-title":"In vitro and in vivo toxicity evaluation of non-neuroleptic phenothiazines, antitubercular drug candidates","volume":"109","author":"Salie","year":"2019","journal-title":"Regulatory toxicology and pharmacology\u202f: RTP"},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0320","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.3762\/bjoc.14.242","article-title":"The design and synthesis of an antibacterial phenothiazine-siderophore conjugate","volume":"14","author":"Tarapdar","year":"2018","journal-title":"Beilstein J. Org. Chem."},{"issue":"19","key":"10.1016\/j.ijbiomac.2025.143541_bb0325","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1016\/j.bmc.2014.07.050","article-title":"Incorporation of triphenylphosphonium functionality improves the inhibitory properties of phenothiazine derivatives in Mycobacterium tuberculosis","volume":"22","author":"Dunn","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112420","article-title":"Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors","volume":"201","author":"Nizi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.143541_bb0335","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects","volume":"67","author":"Cholo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.143541_bb0340","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.5588\/ijtld.11.0752","article-title":"In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters","volume":"16","author":"Xu","year":"2012","journal-title":"The international journal of tuberculosis and lung disease\u202f: the official journal of the International Union against Tuberculosis and Lung Disease"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.143541_bb0345","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3390\/jcm11071927","article-title":"Investigation of Clofazimine resistance and genetic mutations in drug-resistant Mycobacterium tuberculosis isolates","volume":"11","author":"Park","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0350","unstructured":"WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment. (2020). World Health Organization."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0355","doi-asserted-by":"crossref","first-page":"1304857","DOI":"10.3389\/fmed.2023.1304857","article-title":"Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis","volume":"10","author":"Islam","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0360","doi-asserted-by":"crossref","first-page":"1100488","DOI":"10.3389\/fphar.2023.1100488","article-title":"Clofazimine for the treatment of tuberculosis","volume":"14","author":"Stadler","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.143541_bb0365","doi-asserted-by":"crossref","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","article-title":"Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species","volume":"286","author":"Yano","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.143541_bb0370","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1128\/AAC.00395-15","article-title":"Mode of action of Clofazimine and combination therapy with Benzothiazinones against Mycobacterium tuberculosis","volume":"59","author":"Lechartier","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 1","key":"10.1016\/j.ijbiomac.2025.143541_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg212","article-title":"Development of the quinolones","volume":"51","author":"Andersson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.143541_bb0380","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s11030-022-10581-8","article-title":"Quinolone: a versatile therapeutic compound class","volume":"27","author":"Dube","year":"2023","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0385","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ejmech.2018.01.080","article-title":"Fluoroquinolone derivatives and their anti-tubercular activities","volume":"146","author":"Fan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.143541_bb0390","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/molecules26041141","article-title":"Easy-to-access quinolone derivatives exhibiting antibacterial and anti-parasitic activities","volume":"26","author":"Beteck","year":"2021","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.143541_bb0395","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201800141","article-title":"Recent updates of fluoroquinolones as antibacterial agents","volume":"351","author":"Ezelarab","year":"2018","journal-title":"Arch. Pharm."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.143541_bb0400","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1021\/jm00186a014","article-title":"Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids","volume":"23","author":"Koga","year":"1980","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.143541_bb0405","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2174\/156802609789630947","article-title":"Quinolones: action and resistance updated","volume":"9","author":"Drlica","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.143541_bb0410","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1073\/pnas.1525055113","article-title":"Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: enhancing drug activity against wild-type and resistant gyrase","volume":"113","author":"Aldred","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.143541_bb0415","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1128\/EC.00381-08","article-title":"Type II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in toxoplasma gondii","volume":"8","author":"Lin","year":"2009","journal-title":"Eukaryot. Cell"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143541_bb0420","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1021\/jm201184h","article-title":"Identification, design and biological evaluation of heterocyclic quinolones targeting plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2)","volume":"55","author":"Leung","year":"2012","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143541_bb0425","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/jm201179h","article-title":"Identification, design and biological evaluation of bisaryl quinolones targeting plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2)","volume":"55","author":"Pidathala","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0430","doi-asserted-by":"crossref","unstructured":"GA Biagini, N Fisher, AE Shone, MA Mubaraki, A Srivastava, A Hill, T Antoine, AJ Warman, J Davies, C Pidathala, RK Amewu, SC Leung, R Sharma, P Gibbons, DW Hong, B Pacorel, AS Lawrenson, S Charoensutthivarakul, L Taylor, O Berger, A Mbekeani, PA Stocks, GL Nixon, J Chadwick, J Hemingway, MJ Delves, RE Sinden, AM Zeeman, CH Kocken, NG Berry, PM O'Neill, S.A. Ward, (2012). Generation of quinolone antimalarials targeting the plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria. Proc. Natl. Acad. Sci. USA, 109(21), 8298\u20138303. doi:https:\/\/doi.org\/10.1073\/pnas.1205651109.","DOI":"10.1073\/pnas.1205651109"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.143541_bb0435","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.apsb.2021.05.008","article-title":"Design, synthesis, and biological evaluation of multiple targeting antimalarials","volume":"11","author":"Yang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.143541_bb0440","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1021\/acs.jmedchem.6b01718","article-title":"Rational design, synthesis, and biological evaluation of heterocyclic quinolones targeting the respiratory chain of Mycobacterium tuberculosis","volume":"60","author":"Hong","year":"2017","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.143541_bb0445","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/jac\/dkw244","article-title":"Activation of type II NADH dehydrogenase by quinolinequinones mediates antitubercular cell death","volume":"71","author":"Heikal","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.143541_bb0450","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1021\/ml300134b","article-title":"Quinolinyl pyrimidines: potent inhibitors of NDH-2 as a novel class of anti-TB agents","volume":"3","author":"Shirude","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.143541_bb0455","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/acsinfecdis.1c00413","article-title":"Synthesis and in vitro biological evaluation of Quinolinyl pyrimidines targeting type II NADH-dehydrogenase (NDH-2)","volume":"8","author":"Lu","year":"2022","journal-title":"ACS infectious diseases"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.143541_bb0460","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1128\/JB.186.4.928-937.2004","article-title":"Inhibition of membrane-bound methane monooxygenase and ammonia monooxygenase by diphenyliodonium: implications for electron transfer","volume":"186","author":"Shiemke","year":"2004","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0465","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ejmech.2017.10.010","article-title":"Broad activity of diphenyleneiodonium analogues against Mycobacterium tuberculosis, malaria parasites and bacterial pathogens","volume":"148","author":"Nguyen","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.143541_bb0470","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/ph13090227","article-title":"SAR analysis of small molecules interfering with energy-metabolism in Mycobacterium tuberculosis","volume":"13","author":"Appetecchia","year":"2020","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.143541_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075245","article-title":"Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis","volume":"8","author":"Ioerger","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.143541_bb0480","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1021\/acsinfecdis.7b00275","article-title":"2-Mercapto-Quinazolinones as inhibitors of type II NADH dehydrogenase and Mycobacterium tuberculosis: structure-activity relationships, mechanism of action and absorption, distribution, metabolism, and excretion characterization","volume":"4","author":"Murugesan","year":"2018","journal-title":"ACS infectious diseases"},{"key":"10.1016\/j.ijbiomac.2025.143541_bb0485","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tube.2017.11.003","article-title":"The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis","volume":"108","author":"Korkegian","year":"2018","journal-title":"Tuberculosis (Edinb.)"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.143541_bb0490","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/ph16030413","article-title":"Rapid and efficient access to novel bio-inspired 3-dimensional tricyclic SpiroLactams as privileged structures via Meyers\u2019 Lactamization","volume":"16","author":"Tangara","year":"2023","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"24","key":"10.1016\/j.ijbiomac.2025.143541_bb0495","doi-asserted-by":"crossref","first-page":"16651","DOI":"10.1021\/acs.jmedchem.2c01493","article-title":"Tricyclic SpiroLactams kill mycobacteria in vitro and in vivo by inhibiting type II NADH dehydrogenases","volume":"65","author":"Dam","year":"2022","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ijbiomac.2025.143541_bb0500","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.bmcl.2018.05.048","article-title":"\u2018Tethering\u2019 fragment-based drug discovery to identify inhibitors of the essential respiratory membrane protein type II NADH dehydrogenase","volume":"28","author":"Heikal","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.143541_bb0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002251","article-title":"High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism","volume":"7","author":"Griffin","year":"2011","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143541_bb0510","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2958.2003.03425.x","article-title":"Genes required for mycobacterial growth defined by high density mutagenesis","volume":"48","author":"Sassetti","year":"2003","journal-title":"Mol. Microbiol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143541_bb0515","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1038\/s41467-019-12956-2","article-title":"Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development","volume":"10","author":"Beites","year":"2019","journal-title":"Nat. Commun."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025040930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025040930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:03:16Z","timestamp":1782903796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025040930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":103,"alternative-id":["S0141813025040930"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143541","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting type II NADH dehydrogenase in tuberculosis treatment: A review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"143541"}}